15318 NE 95th St
1 article with SystImmune, Inc.
Systimmune Inc. Announces SI-F019 As a Blocker of Viral Entry against SARSCoV-2 with Reduced Inflammatory Risk
Systimmune Inc, a clinical-stage biopharmaceutical company developing multi-specific antibody therapies in oncology, today announces manufacturing development and production of a SARS-CoV-2 neutralizing protein SI-F019 at levels ready for preclinical testing.